Podcasts
Podcast series - What's new in mCRPC?
Lorem ipsum odor amet, consectetuer adipiscing elit. Accumsan ante habitasse, velit per ex suspendisse nibh vulputate accumsan. Suspendisse est id phasellus dapibus facilisis turpis adipiscing libero.
It's great, not only that we have a new treatment, but perhaps even more important that we have a new target, which is prostate-specific membrane antigen (PSMA).
We have to be smart to select the correct patients for immunotherapy in general.
Developed by EPG Health. This content has been developed independently of the sponsor, Pfizer, which has had no editorial input into the content. EPG Health received funding from the sponsor to help provide healthcare professional members with access to the highest quality medical and scientific information, education and associated relevant content. This content is intended for healthcare professionals only.